CFRX - Contrafect

[david_lai]

After the big drop, this is a high risk/reward opportunity.

Phase II definitely demonstrated efficacy of CF-301 towards MRSA, with overall efficacy and statistical significance in bacteremia and right-sided endocarditis.

 

Daptomycin, which was approved more than 10 years ago, also opt for indication bacteremia and right-sided endocarditis. It is just too difficult to treat left-sided endocarditis with medication alone.

 

Hold a position after the big drop, waiting for any deal with bigger pharma and 180 day data. Any further light on Phase III design will also be important at this stage.

[david_lai]

Next week will be quite big for CFRX in this time period, with Phase II new data and also 2 pieces of positive news. Apparently, the Phase 2 new data would be more concerning on safety aspect. After this round of data, I believing the big pharma will start talking to CFRX for partnership since CFRX doesn't really have bargaining power at this low share price.